Title: Impact of outpatient radiotherapy on direct non-medical cost in patients in the Central Macro Region of Peru 2021
Authors: José Fernando Robles Díaz
Section: Conflicts of interest
There are no potential conflicts of interest in this research. Funding No funding has been received. References 1. Zafar SY and Abernethy AP (2013) Financial toxicity, part I: a new name for a growing problem Oncology (Williston Park) 27(2) 80–149 PMID: 23530397 PMCID: 4523887 2. Imber BS, Varghese M, and Ehdaie B, et al (2020) Financial toxicity associated with treatment of localized prostate cancer Nat Rev Urol 17(1) 28–40 https://doi.org/10.1038/s41585-019-0258-3 3. Wallis CJD, Joyce DD, and Klaassen Z, et al (2021) Out-of-pocket costs for commercially insured patients with localized prostate cancer Urol Oncol 39(12) 797–805 https://doi.org/10.1016/j.urolonc.2021.08.026 4. Fabian A, Domschikowski J, and Greiner W, et al (2022) Financial toxicity in cancer patients treated with radiotherapy in Germanya cross-sectional study Strahlenther Onkol 198(12) 1053–1061 https://doi.org/10.1007/s00066-022-01936-z 5. Narang AK and Nicholas LH (2017) Out-of-pocket spending and financial burden among medicare beneficiaries with cancer JAMA Oncol 3(6) 757–765 https://doi.org/10.1001/jamaoncol.2016.4865 PMCID: 5441971 6. Perú, Instituto Nacional de Estadística e Informática (INEI) (2020) Encuesta Nacional de Hogares 2020 [https://www.inei.gob.pe/media/ MenuRecursivo/boletines/informe-condiciones-de-vida.pdf´] Date accessed: 17/07/22 7. Cañizares FW (2017) Evolución del sistema de salud de Perú: buenas prácticas y desafíos en su construcción. Década 2005-2014 An Fac Med 78(4) 445–451 https://doi.org/10.15381/anales.v78i4.14269 Re se ar ch ecancer 2023, 17:1580; www.ecancer.org; DOI: https://doi.org/10.3332/ecancer.2023.1580 8 8. Chino F, Peppercorn JM, and Rushing C, et al (2018) Going for broke: a longitudinal study of patient-reported financial sacrifice in cancer care J Oncol Pract 14(9) e533–e546 https://doi.org/10.1200/JOP.18.00112 PMID: 30138052 PMCID: 6550053 9. Jagsi R, Ward KC, and Abrahamse PH, et al (2018) Unmet need for clinician engagement regarding financial toxicity after diagnosis of breast cancer Cancer 124(18) 3668–3676 https://doi.org/10.1002/cncr.31532 PMID: 30033631 PMCID: 6553459 10. Chino F, Peppercorn JM, and Rushing C, et al (2017) Out-of-pocket costs, financial distress, and underinsurance in cancer care JAMA Oncol 3(11) 1582–1584 https://doi.org/10.1001/jamaoncol.2017.2148 PMID: 28796862 PMCID: 5824215 11. Olivera Changra H and Robles Díaz JF (2022) Costs of intravenous vs. subcutaneous administration of trastuzumab in peruvian patients with HER2-positive breast cancer – an observational analysis of direct and indirect costs J Healthc Qual Res 37(3) 147–154 [Spanish] https://doi.org/10.1016/j.jhqr.2021.10.008 12. Ramsey SD, Bansal A, and Fedorenko CR, et al (2016) Financial insolvency as a risk factor for early mortality among patients with cancer J Clin Oncol 34(9) 980–986 https://doi.org/10.1200/JCO.2015.64.6620 PMID: 26811521 PMCID: 4933128 13. Longo CJ, Fitch MI, and Banfield L, et al (2020) Financial toxicity associated with a cancer diagnosis in publicly funded healthcare countries: a systematic review Support Care Cancer 28(10) 4645–4665 https://doi.org/10.1007/s00520-020-05620-9 PMID: 32653957 14. Perú, Instituto Nacional de Estadística e Informática (INEI) (2018) Evolución